Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin

Hillel Yaffe Medical Center180 enrolled

Overview

The aim of this research is to study the effect of a loading dose of colchicine on the occurrence of periprocedural myocardial infarction (PPMI) in elective percutaneous coronary intervention.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

180

Conditions

Inflammation Myocardial Infarction

Interventions

Colchicine Loading DoseDRUG

Two milligrams of colchicine will be administrated in addition to the standard of care treatment

Standard of care treatment prior to elective PCIDRUG

All medications normally given to patients prior to elective PCI

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients hospitalized with troponin negative events and scheduled for elective PCI Exclusion Criteria: * Significant renal dysfunction * Significant liver dysfunction * Severe left ventricular dysfunction * Severe low weight * Chronic colchicine treatment

Locations (1)

Hille Yaffe Medical Center

Hadera, Israel

Outcomes

Primary Outcomes

Occurrence of PPMI post elective PCI

Occurrence of PPMI post elective PCI and its relation to defensin levels

Time frame: 24 hours post PCI

Secondary Outcomes

Traditional inflammatory markers

Determination of traditional inflammatory markers including c-reactive protein, white blood cells and interleukin-6

Time frame: 24 hours post PCI

Major adverse cardiovascular events

Determining the occurrence of major adverse cardiovascular events

Time frame: 30 days

Central Contacts

Rami Abu Fanne, MD, PhD

CONTACT

972-50-3573694 ramia@hadassah.org.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.